Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
Sign-on Letter Supporting the Saving Access to Laboratory Services Act
-
ACMG Comment to NCD on Germline Editing and Impact on People with Disabilities